Fly News Breaks for December 16, 2019
Dec 16, 2019 | 07:51 EDT
Jefferies analyst David Steinberg increased his price target on Horizon Pharma shares to $40 from $35 after an FDA advisory committee voted 12-0 that the benefits of teprotumumab outweigh the potential risks in treating thyroid eye disease, or TED. While acknowledging that the FDA is not bound by this recommendation, Steinberg sees it as "a strong signal" for approval ahead of the drug's March 8, 2020 PDUFA action date, he tells investors. He keeps a Buy rating on Horizon shares.
News For HZNP From the Last 2 Days
Aug 5, 2021 | 07:52 EDT
BMO Capital analyst Gary Nachman raised the firm's price target on Horizon Therapeutics to $132 from $118 and keeps an Outperform rating on the shares. The company's Q2 result were an "impressive" beat and raise, with the upside driven by Tepeza relaunch following Q1 supply disruption and faster than expected acceleration in demand, the analyst tells investors in a research note. Nachman adds that Horizon's pipeline "remains underappreciated" and is "progressing nicely", which will be highlighted on the company's R&D day.